Global iPSC Cell Therapies Market Growth (Status and Outlook) 2025-2031

The global iPSC Cell Therapies market size is predicted to grow from US$ 10180 million in 2025 to US$ 19920 million in 2031; it is expected to grow at a CAGR of 11.8% from 2025 to 2031.

Induced pluripotent stem cell (iPSC) cell therapy is a cutting-edge regenerative medicine technology that uses somatic cells to be converted into pluripotent stem cells through genetic reprogramming technology, and then differentiate into specific types of cells for the treatment of various diseases. This technology allows scientists to generate corresponding cells from the patient's own cells, reducing the risk of immune rejection.

United States market for iPSC Cell Therapies is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

China market for iPSC Cell Therapies is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Europe market for iPSC Cell Therapies is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Global key iPSC Cell Therapies players cover Bayer(BlueRock Therapeutics), Notch Therapeutics, Evotec Group, Pluristyx, Inc, Cellino, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.

LPI (LP Information)' newest research report, the “iPSC Cell Therapies Industry Forecast” looks at past sales and reviews total world iPSC Cell Therapies sales in 2024, providing a comprehensive analysis by region and market sector of projected iPSC Cell Therapies sales for 2025 through 2031. With iPSC Cell Therapies sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world iPSC Cell Therapies industry.

This Insight Report provides a comprehensive analysis of the global iPSC Cell Therapies landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on iPSC Cell Therapies portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global iPSC Cell Therapies market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for iPSC Cell Therapies and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global iPSC Cell Therapies.

This report presents a comprehensive overview, market shares, and growth opportunities of iPSC Cell Therapies market by product type, application, key players and key regions and countries.

Segmentation by Type:
Preclinical/Research Stage
Clinical Stage
Commercial Stage

Segmentation by Application:
Neurodegenerative Diseases
Cardiovascular Diseases
Diabetes
Other

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Bayer(BlueRock Therapeutics)
Notch Therapeutics
Evotec Group
Pluristyx, Inc
Cellino
Fate Therapeutics
Allogene Therapeutics, Inc.
Takeda Pharmaceutical Company Limited
Century Therapeutics
Resolution Therapeutics
Kenai
Garuda Therapeutics
Hebecell
Allele Biotechnology and Pharmaceuticals
Aspen Neurosciencehttps://www.scispot.com/blog/top-innovative-stem-cell-companies-in-the-us
ElevateBio
iCamumo
BeiGene, Ltd
LumiSTAR Biotechnology
Neukio Biotherapeutics
Help Therapeutics
Hopstem Biotechnology Inc.
Nuwacell Biotechnologies Co., Ltd.
ihan Biotech
iRegene
Allife Medicine
CellOrigin
XellSmart bio
ThinkingBioMed
Cell Inspire Bio
Hema Cell
Yuesai BIO
Cytovia

Please note: The report will take approximately 2 business days to prepare and deliver.